First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.
Marcelo V. Negrão(The University of Texas MD Anderson Cancer Center), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Maria Pia Morelli(The University of Texas MD Anderson Cancer Center), Raffaele Baffa, Drew Deninger, John V. Heymach(The University of Texas MD Anderson Cancer Center), Nathan Demars, Jaymes Holland, Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Matthew R. Collinson-Pautz(Baylor College of Medicine), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Eleanor De Groot, Benny Johnson(The University of Texas MD Anderson Cancer Center)
Cited by 3
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k